EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Age‐Associated Targetable Genomic Alterations and PD ‐ L1 Expression in 2509 Patients With Pulmonary Ground‐Glass Opacities

Wen-Fang Tang, Si-Qi Huang, Yi-Duo Lin, Hong-Ji Li, Qing-Hua Huang, Jing Chen, Zhen-Bin Qiu iD, Wei-Zhao Huang, Ying-Meng Wu, Hong-Yu Ye, Wei Xu, Xue-Ning Yang und 5 weitere

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.05.2026. Verfasst von Wen-Fang Tang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lung Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Medical Association Clinical Research Fund, National Natural Science Foundation of China, Zhongshan Science and Technology Bureau Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the landscape of targetable genomic alterations and programmed cell death ligand 1 (PD‐L1) expression in pulmonary ground‐glass opacities (GGOs) and their association with age.

Methods

A total of 2509 patients with GGOs were retrospectively analyzed. Tumor characteristics, PD‐L1 expression, and prevalence of targetable alterations were compared across age groups.

Results

In GGOs, the mutation rates of EGFR (61.5%) and ERBB2 (12.0%) were relatively high, whereas those of KRAS (8.2%) and ALK rearrangements (2.3%) were relatively low. The patients exhibited a low tumor mutational burden (TMB), and PD‐L1 expression was negative in 86.7% of cases. TMB, PD‐L1 expression, and the mutation rates of EGFR, KRAS, and MET increased significantly with age, whereas the rates of ERBB2 mutations, ALK rearrangements, and RET rearrangements decreased significantly with age. Age was identified as an independent predictor for the above eight variables. The optimal age cutoff was determined to be 53 years. Compared with the younger age group (< 53 years), the older age group (≥ 53 years) showed a 31.6%, 130.4%, and 800.0% higher likelihood of harboring EGFR, KRAS, and MET mutations, respectively. Conversely, compared with the older age group, the younger age group showed a 289.1%, 94.1%, and 108.7% higher likelihood of harboring ERBB2 mutations, ALK rearrangements, and RET rearrangements, respectively.

Conclusions

GGOs exhibit a distinct genomic and PD‐L1 profile with significant age‐related heterogeneity, providing insights for age‐stratified therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLung NeoplasmsHumansMiddle AgedFemaleMutationAge FactorsMaleAdultAgedRetrospective StudiesAged, 80 and overGene RearrangementBiomarkers, Tumor

Stichwörter der Autor:innen

PD‐L1agecorrelationpulmonary ground‐glass opacitiestargetable genomic alterations

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,…
  • Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumor Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
  • Molecular Diagnostic Center, Zhongshan City People's Hospital, Zhongshan, China.
  • Department of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.

ORCID-Profile: Zhen-Bin Qiu

Förderung

  • Guangdong Medical Association Clinical Research Fund
  • National Natural Science Foundation of China
  • Zhongshan Science and Technology Bureau Project
  • Beijing Xisike Clinical Oncology Research Foundation
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China Major Joint Project on Key scientific issues of lung Cancer
  • National High-Level Talents Special Support Program
  • Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer

Zitieren

APA

Tang, W. F., Huang, S. Q., Lin, Y. D., Li, H. J., Huang, Q. H., Chen, J., Qiu, Z. B., Huang, W. Z., Wu, Y. M., Ye, H. Y., Xu, W., Yang, X. N., Wu, Y. L., Jiang, H. M., Liang, Y., Tang, X., & Zhong, W. Z. (2026). Age‐Associated Targetable Genomic Alterations and PD ‐ L1 Expression in 2509 Patients With Pulmonary Ground‐Glass Opacities. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71811

Vancouver

Tang WF, Huang SQ, Lin YD, Li HJ, Huang QH, Chen J, et al. Age‐Associated Targetable Genomic Alterations and PD ‐ L1 Expression in 2509 Patients With Pulmonary Ground‐Glass Opacities. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71811

BibTeX
@article{Tang2026,
  author = {Tang, Wen-Fang and Huang, Si-Qi and Lin, Yi-Duo and Li, Hong-Ji and Huang, Qing-Hua and Chen, Jing and Qiu, Zhen-Bin and Huang, Wei-Zhao and Wu, Ying-Meng and Ye, Hong-Yu and Xu, Wei and Yang, Xue-Ning and Wu, Yi-Long and Jiang, Hai-Ming and Liang, Yi and Tang, Xuan and Zhong, Wen-Zhao},
  title = {Age‐Associated Targetable Genomic Alterations and PD ‐ L1 Expression in 2509 Patients With Pulmonary Ground‐Glass Opacities},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71811}
}
Kostenlos starten →